TABLE 1.
Clinical and laboratory variables of 718 patients with essential thrombocythemia from University of Florence cohort, stratified by their driver mutational status
| Clinical and laboratory variables | All patients (n = 718) | JAK2 (n = 471; 65.6%) | CALR type 1/1 like (n = 92; 12.8%) | CALR type 2/2 like (n = 51; 7.1%) | MPL (n = 26; 3.6%) | TN (n = 78; 10.9%) | p valuesa |
|---|---|---|---|---|---|---|---|
| Age in year; median (range) | 57.9 (12.9–92.9) | 62.0 (14.9–92.9) | 52.6 (12.9–85.1) | 48.9 (20.5–84.4) | 54.8 (37.3–89.2) | 49.2 (15.2–81.3) | <0.001 |
| Age ≥ 60 years; n (%) | 333 (46.4) | 253 (53.7) | 30 (32.6) | 13 (25.5) | 11 (42.3) | 26 (33.3) | <0.001 |
| Sex, females; n (%) | 465 (64.8) | 318 (67.5) | 39 (42.6) | 25 (49.0) | 20 (76.9) | 63 (80.8) | <0.001 |
|
White blood cells × 109/L; median (range) N evaluable = 695 |
8.3 (3.7–18.2) | 8.7 (3.7–18.2) | 8.2 (3.9–18.2) | 7.2 (3.8–14.7) | 6.8 (4.0–16.7) | 7.6 (6.4–13.3) | <0.001 |
|
White blood cells ≥11 × 109/L; n (%) N evaluable = 695 |
114 (16.4) | 90 (19.6) | 11 (12.8) | 2 (4.2) | 5 (20.0) | 6 (7.7) | 0.01 |
| Hemoglobin, g/dl; median (range) | 14.1 (11.5–16.5) | 14.4 (11.8–16.5) | 13.8 (11.8–15.9) | 13.7 (11.9–16.3) | 13.6 (11.9–16.1) | 13.5 (11.5–16.4) | <0.001 |
| Hematocrit, %; median (range) | 42.9 (35.1–51.0) | 43.9 (36.0–50.0) | 41.6 (36.7–47.9) | 41,2 (35,6 – 49,4) | 41.3 (38.0–47.0) | 40.9 (35.1–51.0) | <0.001 |
| Platelets, ×109/L; median (range) | 739 (455–2348) | 698 (455–1881) | 823 (504–2000) | 886 (495–2348) | 851.5 (467–1742) | 794 (460–1700) | <0.001 |
| Platelets ≥ 1000 ×109/L; n (%) | 126 (17.5) | 61 (12.9) | 24 (26.1) | 16 (31.4) | 7 (26.9) | 18 (23.1) | 0.001 |
| Palpable splenomegaly; n (%) | 97 (13.5) | 67 (14.2) | 15 (16.3) | 6 (11.8) | 4 (15.4) | 5 (6.4) | 0.3 |
| Constitutional symptoms; n (%) | 43 (6.0) | 27 (5.7) | 5 (5.4) | 3 (5.9) | 2 (7.7) | 6 (7.7) | 0.9 |
|
Major thrombosis before diagnosis; n (%) N evaluable = 633 |
39 (6.2) | 35 (8.6) | 1 (1,2) | 0 (0) | 0 (0) | 3 (3.8) | 0.01 |
|
Major thrombosis at diagnosis; n (%) N evaluable = 631 |
42 (6.7) | 31 (7.8) | 2 (2,4) | 1(2) | 4 (16.0) | 4 (5.1) | 0.07 |
|
Overall thrombosis at follow‐up; n (%) N evaluable = 715 |
99 (13.8) | 69 (14.7) | 14 (15.4) | 7 (14) | 7 (26.9) | 2 (2.6) | 0.01 |
|
Overall major bleeding; n (%) N evaluable = 713 |
59 (8.3) | 41 (8.7) | 9 (10.0) | 2 (3,9) | 3 (11,5) | 4 (5.1) | 0.5 |
|
Overall minor bleeding; n (%) N evaluable = 709 |
90 (12.7) | 54 (11.6) | 13 (14.4) | 7 (14.3) | 7 (26.9) | 9 (11.5) | 0.2 |
|
Cardiovascular risk factors; n (%) N evaluable = 618 |
327 (52.9) | 235 (59.5) | 34 (44.7) | 15 (34.1) | 12 (48.0) | 31 (39.7) | <0.001 |
|
Microcirculatory symptoms; n (%) N evaluable = 709 |
235 (33.1) | 149 (32.0) | 25 (28.1) | 18 (36) | 16 (61.5) | 27 (34.6) | 0.03 |
| Median follow up; (months), range | 106.4 (6.1–421.6) | 105.9 (6.1–421.6) | 104.9 (7.3–417.9) | 101.1 (12.1–403.5) | 140.3 (17.4–275.1) | 106.6 (8.6–390.9) |
0.7 |
| MF progression; n (%) | 53 (7.4) | 23 (4.9) | 20 (21.7) | 4 (7.9) | 5 (19.2) | 1 (1.3) | <0.001 |
| AML progression; n (%) | 12 (1.7) | 9 (1.9) | 1 (0.7) | 0 (0.0) | 2 (7.7) | 0 (0.0) | 0.08 |
| Death; n (%) |
106 (14.8) |
77 (16.3) | 15 (16.3) | 3 (5.9) | 6 (23.1) | 5 (6.4) | 0.04 |
Abbreviations: TN, triple negative.
a
Significant p values are highlighted in bold.